

# ASX Release

---

## SUDA LTD AUDIO WEBCAST

**PERTH, AUSTRALIA – 9 June 2015:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, provides the opportunity to listen to an audio broadcast with Mr Stephen Carter, SUDA's Managing Director & CEO, in a presentation titled:

"SUDA provides a shareholder update."

**To listen**, copy the following details into your web browser:

<http://brrmedia.com/event/138874>



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA LTD**

Tel: +61 8 6142 5555

[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

**NOTES TO EDITORS:**

**About SUDA LTD**

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)